Contact Lens Spectrum
Issue link: https://clssupplements.epubxp.com/i/740958
c l s p e c t r u m . c o m 51 C O N T A C T L E N S S P E C T R U M S P E C I A L E D I T I O N 2 0 1 6 Dr. Wygladacz is a Senior Research Scientist in Vision Care R&D; at Bausch + Lomb, a division of Valeant Pharmaceuticals International. Dr. Hook is a Senior Principal Scientist at Valeant Pharmaceuticals International, Inc. and Group Leader of the Structural and Surface Science Group within Bausch + Lomb. ings on surface wettability characteristics of silicone hydrogels. Langmuir. 2015;31(13):3820-3828. 10. Lin MC, Svitova TF. Contact lenses wettability in vitro: effect of surface-active ingredients. Optom Vis Sci. 2010;87(6):440-447. 11. Tonge S, Jones L, Goodall S, Tighe B. The ex vivo wettability of soft contact lenses. Curr Eye Res. 2001;23(1):51-59. 12. Ketelson HA, Meadows DM, McQueen N, Stone RP. Enhanc- ing wettability with multi-purpose solutions. Rev Cornea Cont Lens. 2005;142(1 Suppl):44-47. 13. Aragona P. Hyaluronan in the treatment of ocular surface disorders (Chapter 24). In: HG Garg and CA Hales, eds. Chemistry and Biology of Hyaluronan. Oxford: Elsevier Ltd; 2004(pages 529-551). 14. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluro- nan): a review. Vet Med 2008;53:397-411. 15. Brown TJ, Alcorn D, Fraser JR. Absorption of hyaluronan applied to the surface of intact skin. J Invest Dermatol. 1999;113(5):740-746. 16. Johnston JB. A simple, nondestructive assay for bound hyaluronan. J Biomed Mater Res. 2000;53(2):188-191. 17. Laurent TC, Laurent UB, Fraser JR. Functions of hyaluronan. Ann Rheum Dis. 1995;54(5):429-432. 18. FDA 510(k) Summary K121201. Soft (Hydrophilic) Contact Lens, Oct 26, 2012. 19. FDA 510(k) Summary K083757. Bausch & Lomb BPZO2 Multi- Purpose Solution. November 18, 2009. 20. FDA 510k Summary K032030. blink™ CL Lubricant Eye Drops, Sep. 25, 2003. 21. Lerner LE, Schwartz DM, Hwang DG, Howes EL, Stern R. Hyaluro- nan and CD44 in the human cornea and limbal conjunctiva. Exp Eye Res. 1998;67(4):481-484. 22. Wysenbeek YS, Loya N, Ben Sira I, Ophir I, Ben Shaul Y. The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study. Invest Ophthalmol Vis Sci. 1988;29(2):194-199. 23. Johnson ME, Murphy PJ, Boulton M. Effectiveness of sodium hy- aluronate eyedrops in the treatment of dry eye. Graef Arch Clin Exp Ophthalmol. 2006;244(1):109-112. 24. Mengher LS, Pandher KS, Bron AJ, Davey CC. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. Br J Ophthalmol. 1986;70(6):442-447. 25. McCann LC, Tomlinson A, Pearce EI, Papa V. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea. 2012;31(1):1-5. 26. Condon PI, McEwen CG, Wright M, Mackintosh G, Prescott RJ, McDonald C. Double blind, randomised, placebo controlled, cross- over, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol. 1999;83(10):1121-1124. 27. Gonzalez-Meijome JM, Lopez-Alemany A, Almeida JB, Parafita MA, Refojo MF. Microscopic observation of unworn siloxane-hydrogel soft contact lenses by atomic force microscopy. J Biomed Mater Res B Appl Biomater. 2006;76(2):412-418. 28. Teichroeb JH, Forrest JA, Ngai V, Martin JW, Jones L, Medley J. Imaging protein deposits on contact lens materials. Optom Vis Sci. 2008;85(12):1151-1164. 29. Scheuer CA, Fridman KM, Barniak VL, Burke SE, Venkatesh S. Re- tention of conditioning agent hyaluronan on hydrogel contact lenses. Cont Lens Anterior Eye. 2010;33(Suppl 1):S2-S6. 30. Liu XM, Harmon PS, Maziarz EP, Rah MJ, Merchea MM. Compara- tive studies of hyaluronan in marketed ophthalmic products. Optom Vis Sci. 2014;91(1):32-38. 31. Scheuer C, Rah MJ, Reindel WT. Increased concentration of hyal- uronan in tears after soaking contact lens in Biotrue multipurpose solu- tion. Clin Ophthalmol. 2016, in press. 32. Tas J. The Alcian blue and combined Alcian blue--Safranin O stain- ing of glycosaminoglycans studied in a model system and in mast cells. Histochem J. 1977;9(2):205-230. 33. Luo Y, Prestwich GD. Hyaluronic acid-N-hydroxysuccinimide: a useful intermediate for bioconjugation. Bioconjug Chem. 2001;12(6):1085-1088. 34. Homer KA, Denbow L, Whiley RA, Beighton D. Chondroitin sul- fate depolymerase and hyaluronidase activities of viridans streptococci determined by a sensitive spectrophotometric assay. J Clin Microbiol. 1993;31(6):1648-1651. 35. Fagnola M, Pagani MP, Maffioletti S, Tavazzi S, Papagni A. Hyaluronic acid in hydrophilic contact lenses: spectroscopic investi- gation of the content and release in solution. Cont Lens Anterior Eye. 2009;32(3):108-112. 36. Tavazzi S, Tonveronachi M, Fagnola M, et al. Wear effects on micro- scopic morphology and hyaluronan uptake in siloxane-hydrogel contact lenses. J Biomed Mater Res B Appl Biomater. 2015;103(5):1092-1098. 37. Wygladacz K, Bakker E. Fluorescent microsphere fiber optic micro- sensor array for direct iodide detection at low picomolar concentrations. Analyst. 2007;132(3):268-272. 38. Khan AY, Saha B, Suresh Kumar G. Phenazinium dyes safranine O and phenosafranine induce self-structure in single stranded polyadenylic acid: structural and thermodynamic studies. J Photochem Photobiol B. 2014;132:17-26. 39. Weeks A, Boone A, Luensmann D, Jones L, Sheardown H. The effects of hyaluronic acid incorporated as a wetting agent on lyso- zyme denaturation in model contact lens materials. J Biomater Appl. 2013;28(3):323-333. 38. Singh A, Li P, Beachley V, McDonnell P, Elisseeff JH. A hyaluronic acid-binding contact lens with enhanced water retention. Cont Lens Anterior Eye. 2015;38(2):79-84. HY ALURONAN IN LENS CARE Biotrue and PureVision are registered trademarks of Bausch & Lomb Incorporated or its affiliates. UFP.0260.USA.16